Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Research on the inhibiting effect of tanshinone IIA on colon cancer cell growth via COX-2-Wnt/β-catenin signaling pathway.
|
30570856 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer.
|
31100474 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conversely, higher levels of BA and cyclooxygenase-2 (COX-2) are risk factors for inflammation and cancer of the colon.
|
30650553 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the presence of PVT1 decreased the level of miR-146a whereas increasing the messenger RNA and protein levels of COX2, thus establishing a PVT1/miR-146a/COX2 signaling pathway underlying the pathogenesis of CC.
|
30820968 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression.
|
31844085 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Different polysaccharide-rich extracts showed the ability to inhibit pro-inflammatory enzymes (COX-1, COX-2, hyaluronidase), a radical scavenging effect (against DPPH<sup>•</sup> and ABTS<sup>•+</sup>), and antiproliferative activity (in the A549 lung and SW480 colon cancer cell lines) in in vitro assays.
|
30959857 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells.
|
30813251 |
2019 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidemiological and experimental observations have shown that nonsteroidal anti-inflammatory drugs especially selective cyclooxygenase-2 (COX-2) inhibitors and probiotics reduce the incidence risk of colon cancer.
|
30183370 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thereby, the use of COX-2 inhibitor drugs might likely counteract nicotine-mediated EMT effects on colon cancer development and progression.
|
29215713 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models.
|
29899846 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
This paper reviews the current state of knowledge concerning the potential of various dietary polyphenols to inhibit the effects of COX-2 in colon cancer, by examining the available evidence regarding the efficacy and safety of these compounds obtained from in vitro and animal studies.
|
29068698 |
2018 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a subset of 510 patients, the association between marine ω-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11-0.95; <i>P</i><sub>trend</sub> = 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48-1.27; <i>P</i><sub>trend</sub> = 0.35; <i>P</i><sub>interaction</sub> = 0.19).<b>Conclusions:</b> Patients with high intake of marine ω-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.<b>Impact:</b> Randomized controlled trials examining dark fish and/or marine ω-3 PUFA supplements and colon cancer recurrence/survival are needed.
|
29358223 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, ELISA assays revealed that both the compounds had higher inhibition properties to various biomarker of colon cancer like IL-6 and COX-2.
|
28425852 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we identified XRCC5 as a binding protein of the COX-2 gene promoter in colon cancer cells with streptavidin-agarose pulldown assay and mass spectrometry analysis, and found that XRCC5 promoted colon cancer growth through modulation of COX-2 signaling.
|
29049411 |
2017 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results showed the protective effect of daily consumption of rich cooked chickpeas in the carcinogenesis process, decreasing lipid, protein, and DNA oxidation and decreasing the expression of inflammatory enzymes (COX-2 and iNOS) as well as β-catenin, one of the most important oncogenic proteins in colon cancer.
|
28657468 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.
|
28587064 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation of the COX-2/PGE<sub>2</sub> system and COX-2-dependent suppressive events were also observed in ex vivo human breast and colon cancer explant cultures and were similarly counteracted by celecoxib.
|
28212885 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celecoxib and etoricoxib, the two cyclooxygenase-2 (COX-2) selective NSAIDs, and Diclofenac, a preferential COX-2 inhibitory NSAID, had shown uniformly the chemopreventive and anti-neoplastic effects in the early stage of colon cancer by promoting apoptosis as well as an over-expression of GSK-3β while down-regulating the PI3-K/Akt oncogenic pathway.
|
28718684 |
2017 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the overexpression pattern of COX-2 in Smad3 mutant mice that develop colon cancer was identified.
|
28454287 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, immunohistochemical analyses for SphK1 and COX-2 were performed on human colon cancer tissue microarray.
|
28583134 |
2017 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, we here revealed possible involvement of FOXP3 in regulating cCSC self-renewal via tuning COX2 expression, and thus providing a new target for the eradication of colon cancer stem cells.
|
28591725 |
2017 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the loss of APC function favors the silencing of FXR expression through CpG hypermethylation in mouse colonic mucosa and human colon cells, leading to reduced expression of downstream targets (SHP, IBABP) involved in BA homeostasis while increasing the expression of factors (COX-2, c-MYC) that contribute to inflammation and colon cancer.
|
26609171 |
2016 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The above results suggested that the simultaneous blocking of COX-2 and 5-LOX activity may bring more potential benefits in managing the progression of colon cancer.
|
26707712 |
2016 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The co-regulation of 5-LOX and COX-2 in colon cancer growth and its relationship with cigarette smoke and hyaluronic acid-CD44v6 is also described.
|
26997150 |
2016 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent research has demonstrated that colon cancer cell proliferation can be suppressed in the cells that overexpress COX-2 via generating 8-hydroxyoctanoic acid (a free radical byproduct) during dihomo-γ-linolenic acid (DGLA, an ω-6 fatty acid) peroxidation from knocking down cellular delta-5-desaturase (D5D, the key enzyme for converting DGLA to the downstream ω-6, arachidonic acid).
|
27368132 |
2016 |